NO320780B1 - Oral doseringsform og anvendelse av omega-3-polyumettede syrer og et beleggingsmateriale for fremstilling av doseringsformen for behandling av inflammatorisk tarmsykdom. - Google Patents
Oral doseringsform og anvendelse av omega-3-polyumettede syrer og et beleggingsmateriale for fremstilling av doseringsformen for behandling av inflammatorisk tarmsykdom. Download PDFInfo
- Publication number
- NO320780B1 NO320780B1 NO19975218A NO975218A NO320780B1 NO 320780 B1 NO320780 B1 NO 320780B1 NO 19975218 A NO19975218 A NO 19975218A NO 975218 A NO975218 A NO 975218A NO 320780 B1 NO320780 B1 NO 320780B1
- Authority
- NO
- Norway
- Prior art keywords
- dosage form
- acid
- oral dosage
- omega
- coating
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims abstract description 41
- 235000020660 omega-3 fatty acid Nutrition 0.000 title claims abstract description 23
- 239000006186 oral dosage form Substances 0.000 title claims abstract description 17
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 10
- 238000000576 coating method Methods 0.000 title claims description 26
- 239000011248 coating agent Substances 0.000 title claims description 25
- 238000011282 treatment Methods 0.000 title claims description 20
- 239000000463 material Substances 0.000 title claims description 9
- 150000007513 acids Chemical class 0.000 title description 8
- 239000002552 dosage form Substances 0.000 title description 4
- 239000002775 capsule Substances 0.000 claims abstract description 31
- 210000003405 ileum Anatomy 0.000 claims abstract description 10
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 8
- -1 poly(ethylacrylate-methylmethacrylate) Polymers 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 12
- 230000036962 time dependent Effects 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 240000008415 Lactuca sativa Species 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 235000012045 salad Nutrition 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 1
- 210000003692 ilium Anatomy 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 2
- 239000001828 Gelatine Substances 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000021323 fish oil Nutrition 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 10
- 239000007903 gelatin capsule Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 238000010348 incorporation Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 5
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- YZKOXCJYWZCAFW-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylphenol;phenylmethanol Chemical class OCC1=CC=CC=C1.CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 YZKOXCJYWZCAFW-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003153 Eudragit® NE polymer Polymers 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940067573 brown iron oxide Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- XPNLOZNCOBKRNJ-UHFFFAOYSA-N ethyl prop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C=C.COC(=O)C(C)=C XPNLOZNCOBKRNJ-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000004407 iron oxides and hydroxides Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-M mesalaminate(1-) Chemical compound NC1=CC=C(O)C(C([O-])=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-M 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- 125000003810 γ-tocopherol group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9509764.8A GB9509764D0 (en) | 1995-05-15 | 1995-05-15 | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
| PCT/EP1996/002038 WO1996036329A1 (en) | 1995-05-15 | 1996-05-13 | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO975218D0 NO975218D0 (no) | 1997-11-13 |
| NO975218L NO975218L (no) | 1997-11-13 |
| NO320780B1 true NO320780B1 (no) | 2006-01-30 |
Family
ID=10774461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19975218A NO320780B1 (no) | 1995-05-15 | 1997-11-13 | Oral doseringsform og anvendelse av omega-3-polyumettede syrer og et beleggingsmateriale for fremstilling av doseringsformen for behandling av inflammatorisk tarmsykdom. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US5792795A (cs) |
| EP (1) | EP0825858B1 (cs) |
| JP (1) | JPH11509523A (cs) |
| KR (1) | KR100427112B1 (cs) |
| CN (1) | CN1104237C (cs) |
| AT (1) | ATE294575T1 (cs) |
| AU (1) | AU702692B2 (cs) |
| BR (1) | BR9608785A (cs) |
| CA (1) | CA2221356C (cs) |
| CZ (1) | CZ288560B6 (cs) |
| DE (1) | DE69634693T2 (cs) |
| DK (1) | DK0825858T3 (cs) |
| ES (1) | ES2240995T3 (cs) |
| GB (1) | GB9509764D0 (cs) |
| HU (1) | HU227282B1 (cs) |
| IL (1) | IL118240A (cs) |
| NO (1) | NO320780B1 (cs) |
| PL (1) | PL184085B1 (cs) |
| PT (1) | PT825858E (cs) |
| SK (1) | SK282062B6 (cs) |
| TW (1) | TW397683B (cs) |
| WO (1) | WO1996036329A1 (cs) |
| ZA (1) | ZA963854B (cs) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6166024A (en) | 1995-03-30 | 2000-12-26 | Mayo Foundation For Medical Education And Research | Use of topical azathioprine and thioguanine to treat colorectal adenomas |
| GB9509764D0 (en) * | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
| JP4309045B2 (ja) * | 1997-10-30 | 2009-08-05 | 森下仁丹株式会社 | 不飽和脂肪酸またはその誘導体を内容物とするカプセル製剤およびその製造法 |
| ATE241363T1 (de) * | 1998-02-11 | 2003-06-15 | Rtp Pharma Corp | Ungesättigte fettsäure und steroide enthaltende kombinationspräparate zur behandlung von entzündungen |
| US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| DE19930030B4 (de) * | 1999-06-30 | 2004-02-19 | Meduna Arzneimittel Gmbh | CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform |
| US6358939B1 (en) | 1999-12-21 | 2002-03-19 | Northern Lights Pharmaceuticals, Llc | Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease |
| US6989377B2 (en) | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
| JP2004514730A (ja) * | 2000-12-06 | 2004-05-20 | エス エル エー ファーマ エージー | 固体状ポリ不飽和脂肪酸組成物 |
| US6548646B1 (en) * | 2001-08-23 | 2003-04-15 | Bio-Rad Laboratories, Inc. | Reference control for high-sensitivity C-reactive protein testing |
| AU2002352726A1 (en) * | 2001-11-15 | 2003-06-10 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
| US20030118329A1 (en) * | 2001-12-21 | 2003-06-26 | Pere Obrador | Video indexing using high resolution still images |
| EP2295529B2 (en) * | 2002-07-11 | 2022-05-18 | Basf As | Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use |
| SE0202188D0 (sv) * | 2002-07-11 | 2002-07-11 | Pronova Biocare As | A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| AU2002951913A0 (en) * | 2002-10-08 | 2002-10-24 | Chevis Agriservices & Consulting Pty. Limited | Method of treatment |
| US20050152969A1 (en) * | 2004-01-08 | 2005-07-14 | Chiprich Timothy B. | Colored liquid-filled soft capsules and method of manufacture thereof |
| AU2005206473B2 (en) | 2004-01-12 | 2011-11-10 | Mentrik Biotech, Llc | Fc region variants |
| EP1722630A4 (en) * | 2004-01-20 | 2009-05-27 | Richard F Harty | COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| GB0403247D0 (en) * | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
| GB0413730D0 (en) * | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
| GB0413729D0 (en) * | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
| US8758814B2 (en) | 2004-10-08 | 2014-06-24 | Mcneil-Ppc, Inc. | Chewable enteric coated aspirin tablets |
| WO2009009040A2 (en) * | 2007-07-06 | 2009-01-15 | Baum Seth J | Fatty acid compositions and methods of use |
| US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| AU2009288066B2 (en) | 2008-09-02 | 2015-12-24 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| US20100130608A1 (en) * | 2008-10-01 | 2010-05-27 | Martek Biosciences Corporation | Compositions and methods for reducing triglyceride levels |
| WO2010042933A2 (en) | 2008-10-10 | 2010-04-15 | Northwestern University | Inhibition and treatment of prostate cancer metastasis |
| CN104146955A (zh) | 2009-03-09 | 2014-11-19 | 普罗诺瓦生物医药挪威公司 | 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途 |
| US9901551B2 (en) * | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
| MX2011011517A (es) | 2009-04-29 | 2012-06-19 | Amarin Corp Plc | Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo. |
| MX2011011538A (es) | 2009-04-29 | 2012-06-13 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
| CN108096235A (zh) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
| WO2011038122A1 (en) | 2009-09-23 | 2011-03-31 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| CN102724972A (zh) | 2009-10-23 | 2012-10-10 | 普罗诺瓦生物医药挪威公司 | 脂肪酸油混合物的包衣胶囊和包衣片剂 |
| WO2012054523A2 (en) | 2010-10-19 | 2012-04-26 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| NZ611606A (en) | 2010-11-29 | 2015-10-30 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| KR101310710B1 (ko) * | 2011-03-23 | 2013-09-27 | 한미약품 주식회사 | 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물 |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
| WO2013103958A1 (en) | 2012-01-06 | 2013-07-11 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| SG11201403805WA (en) | 2012-01-06 | 2014-08-28 | Omthera Pharmaceuticals Inc | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
| US8551551B2 (en) | 2012-01-06 | 2013-10-08 | Perlman Consulting, Llc | Stabilization of omega-3 fatty acids in saturated fat microparticles having low linoleic acid content |
| AR095182A1 (es) | 2012-05-07 | 2015-09-30 | Omthera Pharmaceuticals Inc | Composiciones de estatinas y ácidos grasos omega-3 |
| SMT202400504T1 (it) | 2012-06-29 | 2025-01-14 | Amarin Pharmaceuticals Ie Ltd | Metodi per ridurre il rischio di un evento cardiovascolare in un soggetto in terapia con statine |
| GB201216385D0 (en) | 2012-09-13 | 2012-10-31 | Chrysalis Pharma Ag | A pharmaceutical composition |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| EP2745709A1 (en) * | 2012-12-24 | 2014-06-25 | Abbott Laboratories, Inc. | Nutritional compositions with reduced beta-casein a1 and related methods |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| EP3215149A4 (en) | 2014-11-06 | 2018-06-27 | Northwestern University | Inhibition of cancer cell motility |
| MA41611A (fr) | 2015-02-23 | 2018-01-02 | Omthera Pharmaceuticals Inc | Préparations en milli-capsules comprenant des acides gras polyinsaturés libres |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| FR3061151B1 (fr) * | 2016-12-26 | 2019-05-24 | Belles Feuilles | Procede et systeme pour conditionner un compose lipidique en doses, capsules de compose lipidique ainsi obtenues et applications de ces capsules. |
| FR3061019B1 (fr) * | 2016-12-26 | 2019-05-24 | Belles Feuilles | Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments. |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| MX2021002553A (es) | 2018-09-24 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Metodos para reducir el riesgo de eventos cardiovasculares en un sujeto. |
| KR200490037Y1 (ko) | 2019-04-17 | 2019-09-11 | 트랜드 주식회사 | 원터치 작동방식 욕실 청소용 물분사 헤드 |
| US12342842B2 (en) | 2019-05-23 | 2025-07-01 | Evonik Operations Gmbh | Preparation for use in enhancing formation of short-chain fatty acids (SCFAs) |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8505569D0 (sv) * | 1985-11-25 | 1985-11-25 | Aco Laekemedel Ab | Enteralt preparat |
| DE3863678D1 (de) * | 1987-04-27 | 1991-08-22 | Efamol Holdings | Lithiumsalze enthaltende pharmazeutische zubereitungen. |
| US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
| GB2223943A (en) * | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
| EP0670717B1 (en) * | 1992-11-30 | 1998-11-25 | Pfizer Inc. | Supported liquid membrane delivery devices |
| US5411988A (en) * | 1993-10-27 | 1995-05-02 | Bockow; Barry I. | Compositions and methods for inhibiting inflammation and adhesion formation |
| GB9509764D0 (en) * | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
-
1995
- 1995-05-15 GB GBGB9509764.8A patent/GB9509764D0/en active Pending
-
1996
- 1996-05-09 TW TW085105489A patent/TW397683B/zh not_active IP Right Cessation
- 1996-05-13 ES ES96916052T patent/ES2240995T3/es not_active Expired - Lifetime
- 1996-05-13 SK SK1523-97A patent/SK282062B6/sk not_active IP Right Cessation
- 1996-05-13 DE DE69634693T patent/DE69634693T2/de not_active Expired - Lifetime
- 1996-05-13 EP EP96916052A patent/EP0825858B1/en not_active Expired - Lifetime
- 1996-05-13 CN CN96193911A patent/CN1104237C/zh not_active Expired - Lifetime
- 1996-05-13 CZ CZ19973607A patent/CZ288560B6/cs not_active IP Right Cessation
- 1996-05-13 IL IL11824096A patent/IL118240A/xx not_active IP Right Cessation
- 1996-05-13 JP JP8534539A patent/JPH11509523A/ja active Pending
- 1996-05-13 HU HU9900337A patent/HU227282B1/hu unknown
- 1996-05-13 AT AT96916052T patent/ATE294575T1/de active
- 1996-05-13 WO PCT/EP1996/002038 patent/WO1996036329A1/en active IP Right Grant
- 1996-05-13 KR KR1019970708110A patent/KR100427112B1/ko not_active Expired - Lifetime
- 1996-05-13 US US08/687,329 patent/US5792795A/en not_active Expired - Lifetime
- 1996-05-13 CA CA002221356A patent/CA2221356C/en not_active Expired - Lifetime
- 1996-05-13 PT PT96916052T patent/PT825858E/pt unknown
- 1996-05-13 AU AU58955/96A patent/AU702692B2/en not_active Expired
- 1996-05-13 BR BR9608785A patent/BR9608785A/pt not_active IP Right Cessation
- 1996-05-13 DK DK96916052T patent/DK0825858T3/da active
- 1996-05-13 PL PL96323362A patent/PL184085B1/pl unknown
- 1996-05-15 ZA ZA9603854A patent/ZA963854B/xx unknown
-
1997
- 1997-11-13 NO NO19975218A patent/NO320780B1/no not_active IP Right Cessation
-
1998
- 1998-04-30 US US09/069,751 patent/US5948818A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO320780B1 (no) | Oral doseringsform og anvendelse av omega-3-polyumettede syrer og et beleggingsmateriale for fremstilling av doseringsformen for behandling av inflammatorisk tarmsykdom. | |
| Seidner et al. | An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial | |
| Morlion et al. | The effect of parenteral fish oil on leukocyte membrane fatty acid composition and leukotriene-synthesizing capacity in patients with postoperative trauma | |
| RU2505292C2 (ru) | Способы лечения гипертриглицеридемии | |
| US20190183839A1 (en) | Methods of treating pediatric metabolic syndrome | |
| EA011637B1 (ru) | Лечение с использованием омега-3 жирных кислот и агониста и/или антагониста ppar и их комбинированный продукт | |
| US8258188B2 (en) | Method of using punicic acid to enhance immune response and prevent metabolic disorders | |
| US20140275252A1 (en) | Methods of treating traumatic brain injury | |
| JPH02243623A (ja) | 脂肪酸による治療および組成物 | |
| US12427171B2 (en) | Krill oil composition enriched in LPC-DHA and LPC-EPA | |
| JP2021529167A (ja) | ドライアイ疾患及び瞼板腺炎の治療のための組成物 | |
| CN105997973A (zh) | 用于角膜上皮病变和/或结膜上皮病变的治疗剂或预防剂 | |
| Jacobson et al. | Intestinal responsiveness to experimental colitis in young rats is altered by maternal diet | |
| GB2300807A (en) | Oral dosage forms of omega-3 polyunsaturated acids for the treatment of inflammatory bowel disease | |
| Faulkner | The role of omega-3 essential fatty acids in dry eye disease | |
| Mozaffarian et al. | Fish oil: Physiologic effects and administration | |
| HAZRA et al. | Pharmacology and therapeutic potential of the n-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in fish oils | |
| MXPA97008758A (en) | Treatment of inflammatory bowel disease using formats of oral dose of acids 3-omega-poliinsatura | |
| US20200085774A1 (en) | Omega-3 Fatty Acid Composition for Preventing and/or Treating Cachexia | |
| RU2797547C2 (ru) | Способы лечения гипертриглицеридемии | |
| RU2387448C2 (ru) | Незаменимые жирные кислоты, предназначенные для предупреждения и/или лечения депрессии у пациентов, страдающих коронарной болезнью сердца или болезнью коронарной артерии | |
| JPH07233062A (ja) | 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物 | |
| Valsta et al. | Effect of low saturated fat diet on serum lipids in healthy subjects with different apo E phenotypes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |